

Wing Leung

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3830580/publications.pdf>

Version: 2024-02-01

124
papers

8,036
citations

61984

43
h-index

51608

86
g-index

127
all docs

127
docs citations

127
times ranked

8603
citing authors

#	ARTICLE	IF	CITATIONS
1	Successful haploidentical hematopoietic stem cell transplantation (HSCT) and durable engraftment by repeated donor lymphocyte infusions for a Chinese patient with transfusionâ€dependent hemoglobin (Hb) Hammersmith and massive splenomegaly. <i>Pediatric Transplantation</i> , 2022, 26, e14278.	1.0	2
2	A validated pediatric disease risk index for allogeneic hematopoietic cell transplantation. <i>Blood</i> , 2021, 137, 983-993.	1.4	20
3	Irradiationâ€free RIC HSCT has a tolerable safety profile and is effective therapy for pediatric bone marrow failure syndromes. <i>Pediatric Transplantation</i> , 2021, 25, e13855.	1.0	2
4	Excellent Survival Outcomes of Pediatric Patients With Acute Myeloid Leukemia Treated With the MASPORE 2006 Protocol. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, e290-e300.	0.4	1
5	Outcomes of allogeneic transplantation for hemoglobin Bartâ€™s hydrops fetalis syndrome in Hong Kong. <i>Pediatric Transplantation</i> , 2021, 25, e14037.	1.0	7
6	A Phase 2 Trial of KIR-Mismatched Unrelated Donor Transplantation Using in Vivo T Cell Depletion with Antithymocyte Globulin in Acute Myelogenous Leukemia: Children's Oncology Group AAML05P1 Study. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 712-717.	2.0	8
7	Improved survival rate in T-cell depleted haploidentical hematopoietic cell transplantation over the last 15 years at a single institution. <i>Bone Marrow Transplantation</i> , 2020, 55, 929-938.	2.4	31
8	Rapid production of clinicalâ€grade SARSâ€CoVâ€2 specific T cells. <i>Advances in Cell and Gene Therapy</i> , 2020, 3, e101.	0.9	24
9	Effectiveness of Bath Wipes After Hematopoietic Cell Transplantation: A Randomized Trial. <i>Journal of Pediatric Oncology Nursing</i> , 2020, 37, 390-397.	1.5	0
10	Longâ€term results of the <sc>NFâ€08â€TM</sc> protocol in stem cell transplant for patients with thalassemia major: A multiâ€center largeâ€sample study. <i>American Journal of Hematology</i> , 2020, 95, E297-E299.	4.1	9
11	A Distinct Subset of Highly Proliferative and Lentiviral Vector (LV)-Transducible NK Cells Define a Readily Engineered Subset for Adoptive Cellular Therapy. <i>Frontiers in Immunology</i> , 2019, 10, 2001.	4.8	51
12	Allogeneic<sc>CD</sc>27â€depleted cells in adoptive cell therapy. <i>Advances in Cell and Gene Therapy</i> , 2019, 2, e45.	0.9	1
13	A phase II clinical trial of adoptive transfer of haploidentical natural killer cells for consolidation therapy of pediatric acute myeloid leukemia. , 2019, 7, 81.		74
14	Donor lymphocyte infusion and methotrexate for immune recovery after Tâ€cell depleted haploidentical transplantation. <i>American Journal of Hematology</i> , 2018, 93, 169-178.	4.1	9
15	Selective Tâ€cell depletion targeting <sc>CD</sc>45<sc>RA</sc> reduces viremia and enhances early Tâ€cell recovery compared with <sc>CD</sc>3â€targeted Tâ€cell depletion. <i>Transplant Infectious Disease</i> , 2018, 20, e12823.	1.7	46
16	Treosulfan, Fludarabine, and Low-Dose Total Body Irradiation for Children and Young Adults with Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Allogeneic Hematopoietic Cell Transplantation: Prospective Phase II Trial of the Pediatric Blood and Marrow Transplant Consortium. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1651-1656.	2.0	18
17	A Pilot Trial of Humanized Anti-GD2 Monoclonal Antibody (hu14.18K322A) with Chemotherapy and Natural Killer Cells in Children with Recurrent/Refractory Neuroblastoma. <i>Clinical Cancer Research</i> , 2017, 23, 6441-6449.	7.0	116
18	Consolidation Therapy for Newly Diagnosed Pediatric Patients with High-Risk Neuroblastoma Using Busulfan/Melphalan, Autologous Hematopoietic Cell Transplantation, Anti-GD2 Antibody, Granulocyte-Macrophage Colonyâ€Stimulating Factor, Interleukin-2, and Haploidentical Natural Killer Cells. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1910-1917.	2.0	35

#	ARTICLE	IF	CITATIONS
19	Memory T Cells Expressing an NKG2D-CAR Efficiently Target Osteosarcoma Cells. <i>Clinical Cancer Research</i> , 2017, 23, 5824-5835.	7.0	67
20	Successful engraftment determined by the quality rather than quantity of the haematopoietic graft: a lesson from cord blood transplantation of unrelated cord blood and mobilized haploidentical peripheral blood in monozygotic twins. <i>British Journal of Haematology</i> , 2017, 179, 677-679.	2.5	1
21	KIR2DL2/2DL3-E35 alleles are functionally stronger than -Q35 alleles. <i>Scientific Reports</i> , 2016, 6, 23689.	3.3	13
22	SVSI: Fast and Powerful Set-Valued System Identification Approach to Identifying Rare Variants in Sequencing Studies for Ordered Categorical Traits. <i>Annals of Human Genetics</i> , 2015, 79, 294-309.	0.8	9
23	Caregiver and health care provider preferences of nutritional support in a hematopoietic stem cell transplant unit. <i>Pediatric Blood and Cancer</i> , 2015, 62, 1473-1476.	1.5	17
24	Impact of Adenoviral Stool Load on Adenoviremia in Pediatric Hematopoietic Stem Cell Transplant Recipients. <i>Pediatric Infectious Disease Journal</i> , 2015, 34, 562-565.	2.0	22
25	PRL-3 Mediates the Protein Maturation of ULBP2 by Regulating the Tyrosine Phosphorylation of HSP60. <i>Journal of Immunology</i> , 2015, 194, 2930-2941.	0.8	17
26	Genome-wide single-nucleotide polymorphism analysis revealed SUFU suppression of acute graft-versus-host disease through downregulation of HLA-DR expression in recipient dendritic cells. <i>Scientific Reports</i> , 2015, 5, 11098.	3.3	16
27	An Improved Method With High Specificity for KIR2DL1 Functional Allele Typing. <i>Laboratory Medicine</i> , 2015, 46, 207-213.	1.2	2
28	Escalation to High-Dose Defibrotide in Patients with Hepatic Venous Occlusive Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 2148-2153.	2.0	11
29	Haploidentical stem cell transplantation augmented by CD45RA negative lymphocytes provides rapid engraftment and excellent tolerability. <i>Pediatric Blood and Cancer</i> , 2015, 62, 666-673.	1.5	46
30	Routine Pre- and Post-Hematopoietic Stem Cell Transplant Computed Tomography of the Abdomen for Detecting Invasive Fungal Infection Has Limited Value. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1132-1135.	2.0	5
31	Natural killer cell therapy in children with relapsed leukemia. <i>Pediatric Blood and Cancer</i> , 2015, 62, 1468-1472.	1.5	39
32	Gamma Delta T Cell Reconstitution Is Associated with Fewer Infections and Improved Event-Free Survival after Hematopoietic Stem Cell Transplantation for Pediatric Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 130-136.	2.0	92
33	Prognostic factors in children with acute myeloid leukaemia and excellent response to remission induction therapy. <i>British Journal of Haematology</i> , 2015, 168, 94-101.	2.5	31
34	Prospective evaluation for respiratory pathogens in children with sickle cell disease and acute respiratory illness. <i>Pediatric Blood and Cancer</i> , 2014, 61, 507-511.	1.5	14
35	Cognitive Outcome After Pediatric Stem-Cell Transplantation: Impact of Age and Total-Body Irradiation. <i>Journal of Clinical Oncology</i> , 2014, 32, 3982-3988.	1.6	54
36	NK Cell Genotype and Phenotype at Diagnosis of Acute Lymphoblastic Leukemia Correlate with Postinduction Residual Disease. <i>Clinical Cancer Research</i> , 2014, 20, 5986-5994.	7.0	36

#	ARTICLE	IF	CITATIONS
37	Treatment of Hepatoblastoma With High-dose Chemotherapy and Stem Cell Rescue. <i>Journal of Pediatric Hematology/Oncology</i> , 2014, 36, 362-368.	0.6	10
38	Pre-emptive Hematopoietic Stem Cell Transplant Lung Function and Pulmonary Complications in Children. <i>Annals of the American Thoracic Society</i> , 2014, 11, 1576-1585.	3.2	18
39	Infusions of Allogeneic Natural Killer Cells as Cancer Therapy. <i>Clinical Cancer Research</i> , 2014, 20, 3390-3400.	7.0	86
40	Phase I Study of the Safety and Pharmacokinetics of Plerixafor in Children Undergoing a Second Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed or Refractory Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1224-1228.	2.0	10
41	A new set-valued system identification approach to identifying rare genetic variants for ordered categorical phenotype. <i>BMC Bioinformatics</i> , 2014, 15, .	2.6	0
42	TOX2 regulates human natural killer cell development by controlling T-BET expression. <i>Blood</i> , 2014, 124, 3905-3913.	1.4	66
43	Transplant Outcome of Pediatric and Young Adult Patients with Aplastic Anemia: St Jude Children's Research Hospital Experience. <i>Blood</i> , 2014, 124, 1210-1210.	1.4	0
44	Depletion of CD45RA+ Cells from Mobilized Peripheral Blood Stem Cell (PBSC) Collections As an Integral Part of Hematopoietic Stem Cell Transplantation (HSCT) and Cellular Therapy (CT). <i>Blood</i> , 2014, 124, 1130-1130.	1.4	0
45	Timeline, Epidemiology, and Risk Factors for Bacterial, Fungal, and Viral Infections in Children and Adolescents after Allogeneic Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 94-101.	2.0	110
46	Multiplex and Genome-Wide Analyses Reveal Distinctive Properties of KIR+ and CD56+ T Cells in Human Blood. <i>Journal of Immunology</i> , 2013, 191, 1625-1636.	0.8	62
47	Phase I and Clinical Pharmacology Study of Bevacizumab, Sorafenib, and Low-Dose Cyclophosphamide in Children and Young Adults with Refractory/Recurrent Solid Tumors. <i>Clinical Cancer Research</i> , 2013, 19, 236-246.	7.0	64
48	Successful Allogeneic Hematopoietic Cell Engraftment after a Minimal Conditioning Regimen in Children with Relapsed or Refractory Solid Tumors. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 291-297.	2.0	7
49	Natural killer cell therapy for cancer: delivering on a promise. <i>Transfusion</i> , 2013, 53, 245-248.	1.6	2
50	Long-Term Outcome and Evaluation of Organ Function in Pediatric Patients Undergoing Haploidentical and Matched Related Hematopoietic Cell Transplantation for Sickle Cell Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 820-830.	2.0	127
51	Clinical significance of minimal residual disease in patients with acute leukaemia undergoing haematopoietic stem cell transplantation. <i>British Journal of Haematology</i> , 2013, 162, 147-161.	2.5	80
52	Detection of respiratory viruses in asymptomatic children undergoing allogeneic hematopoietic cell transplantation. <i>Pediatric Blood and Cancer</i> , 2013, 60, 149-151.	1.5	16
53	Effect of Donor KIR2DL1 Allelic Polymorphism on the Outcome of Pediatric Allogeneic Hematopoietic Stem-Cell Transplantation. <i>Journal of Clinical Oncology</i> , 2013, 31, 3782-3790.	1.6	57
54	Modulation of NKG2D ligand expression and metastasis in tumors by spironolactone via RXR β activation. <i>Journal of Experimental Medicine</i> , 2013, 210, 2675-2692.	8.5	52

#	ARTICLE	IF	CITATIONS
55	<i>Ex Vivo</i> Activation of CD56+ Immune Cells That Eradicate Neuroblastoma. <i>Cancer Research</i> , 2013, 73, 2608-2618.	0.9	25
56	Prospective Detection of Respiratory Pathogens in Symptomatic Children With Cancer. <i>Pediatric Infectious Disease Journal</i> , 2013, 32, e99-e104.	2.0	37
57	Treatment Outcomes in Black and White Children With Cancer: Results From the SEER Database and St Jude Children's Research Hospital, 1992 Through 2007. <i>Journal of Clinical Oncology</i> , 2012, 30, 2005-2012.	1.6	104
58	Longitudinal Changes in Body Mass and Composition in Survivors of Childhood Hematologic Malignancies After Allogeneic Hematopoietic Stem-Cell Transplantation. <i>Journal of Clinical Oncology</i> , 2012, 30, 3991-3997.	1.6	52
59	Impact of immune modulation with in vivo T-cell depletion and myeloablative total body irradiation conditioning on outcomes after unrelated donor transplantation for childhood acute lymphoblastic leukemia. <i>Blood</i> , 2012, 119, 6155-6161.	1.4	40
60	Antibody-Dependent Cell-Mediated Cytotoxicity Overcomes NK Cell Resistance in <i>MLL</i> -Rearranged Leukemia Expressing Inhibitory KIR Ligands but Not Activating Ligands. <i>Clinical Cancer Research</i> , 2012, 18, 6296-6305.	7.0	33
61	Detectable minimal residual disease before hematopoietic cell transplantation is prognostic but does not preclude cure for children with very-high-risk leukemia. <i>Blood</i> , 2012, 120, 468-472.	1.4	176
62	Phase I Study of the Tolerability and Pharmacokinetics of Palifermin in Children Undergoing Allogeneic Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 1309-1314.	2.0	21
63	Effects of Conditioning Regimens and T Cell Depletion in Hematopoietic Cell Transplantation for Primary Immune Deficiency. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 1911-1920.	2.0	7
64	Prediction of CD34 + cell yield in hematopoietic cell products from children by peripheral blood CD34 + cell counts. <i>Cytotherapy</i> , 2012, 14, 473-482.	0.7	15
65	Comparative Analysis of Different Approaches to Measure Treatment Response in Acute Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2012, 30, 3625-3632.	1.6	188
66	A clinically adaptable method to enhance the cytotoxicity of natural killer cells against B-cell malignancies. <i>Cytotherapy</i> , 2012, 14, 830-840.	0.7	149
67	Combination chemotherapy with clofarabine, cyclophosphamide, and etoposide in children with refractory or relapsed haematological malignancies. <i>British Journal of Haematology</i> , 2012, 156, 275-279.	2.5	16
68	Longitudinal analysis of antibody response to immunization in paediatric survivors after allogeneic haematopoietic stem cell transplantation. <i>British Journal of Haematology</i> , 2012, 156, 109-117.	2.5	37
69	Blood Dendritic Cells Suppress NK Cell Function and Increase the Risk of Leukemia Relapse after Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, 598-607.	2.0	23
70	High success rate of hematopoietic cell transplantation regardless of donor source in children with very high-risk leukemia. <i>Blood</i> , 2011, 118, 223-230.	1.4	157
71	Use of NK cell activity in cure by transplant. <i>British Journal of Haematology</i> , 2011, 155, 14-29.	2.5	110
72	Molecular determinant-based typing of KIR alleles and KIR ligands. <i>Clinical Immunology</i> , 2011, 138, 274-281.	3.2	25

#	ARTICLE	IF	CITATIONS
73	Favorable preliminary results using TLI/ATG-based immunomodulatory conditioning for matched unrelated donor allogeneic hematopoietic stem cell transplantation in pediatric severe aplastic anemia. <i>Pediatric Transplantation</i> , 2011, 15, 628-634.	1.0	10
74	Improved Prognosis for Older Adolescents With Acute Lymphoblastic Leukemia. <i>Journal of Clinical Oncology</i> , 2011, 29, 386-391.	1.6	122
75	Comparing Administration of Nutrition Support With Prescribed Dose. <i>Journal of Pediatric Oncology Nursing</i> , 2011, 28, 273-286.	1.5	3
76	Longitudinal Analysis of Body Mass and Composition in Survivors of Pediatric Hematological Malignancies After Allogeneic Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2011, 118, 1991-1991.	1.4	0
77	Pulmonary dysfunction in survivors of childhood hematologic malignancies after allogeneic hematopoietic stem cell transplantation. <i>Cancer</i> , 2010, 116, 2020-2030.	4.1	53
78	Deficient innate immunity, thymopoiesis, and gene expression response to radiation in survivors of childhood acute lymphoblastic leukemia. <i>Cancer Epidemiology</i> , 2010, 34, 303-308.	1.9	19
79	Phase I Study of Vandetanib During and After Radiotherapy in Children With Diffuse Intrinsic Pontine Glioma. <i>Journal of Clinical Oncology</i> , 2010, 28, 4762-4768.	1.6	108
80	NKAML: A Pilot Study to Determine the Safety and Feasibility of Haploidentical Natural Killer Cell Transplantation in Childhood Acute Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2010, 28, 955-959.	1.6	563
81	Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial. <i>Lancet Oncology</i> , The, 2010, 11, 543-552.	10.7	514
82	KIR-HLA receptor-ligand mismatch associated with a graft-versus-tumor effect in haploidentical stem cell transplantation for pediatric metastatic solid tumors. <i>Pediatric Blood and Cancer</i> , 2009, 53, 120-124.	1.5	64
83	Iron overload in survivors of childhood leukemia after allogeneic hematopoietic stem cell transplantation. <i>Pediatric Transplantation</i> , 2009, 13, 348-352.	1.0	31
84	Total and Active Rabbit Antithymocyte Globulin (rATG;Thymoglobulin®) Pharmacokinetics in Pediatric Patients Undergoing Unrelated Donor Bone Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 274-278.	2.0	47
85	Clinical Utility of Computed Tomography Screening of Chest, Abdomen, and Sinuses before Hematopoietic Stem Cell Transplantation: The St. Jude Experience. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 490-495.	2.0	24
86	Treating Childhood Acute Lymphoblastic Leukemia without Cranial Irradiation. <i>New England Journal of Medicine</i> , 2009, 360, 2730-2741.	27.0	1,059
87	Immunotherapy in Acute Leukemia. <i>Seminars in Hematology</i> , 2009, 46, 89-99.	3.4	9
88	Significant functional heterogeneity among KIR2DL1 alleles and a pivotal role of arginine245. <i>Blood</i> , 2009, 114, 5182-5190.	1.4	100
89	Longitudinal Analysis of Antibody Response to Immunization in Pediatric Survivors After Allogeneic Hematopoietic Stem Cell Transplantation.. <i>Blood</i> , 2009, 114, 795-795.	1.4	0
90	Pulmonary Function in Pediatric survivors of non-Malignant Disorders after Allogeneic Hematopoietic Stem Cell Transplantation.. <i>Blood</i> , 2008, 112, 2136-2136.	1.4	1

#	ARTICLE	IF	CITATIONS
91	A Prospective Cohort Study of Late Sequelae of Pediatric Allogeneic Hematopoietic Stem Cell Transplantation. <i>Medicine (United States)</i> , 2007, 86, 215-224.	1.0	104
92	Diagnostic Yield of Bronchoalveolar Lavage Is Low in Allogeneic Hematopoietic Stem Cell Recipients Receiving Immunosuppressive Therapy or with Acute Graft-versus-Host Disease: The St. Jude Experience, 1990-2002. <i>Biology of Blood and Marrow Transplantation</i> , 2007, 13, 831-837.	2.0	36
93	Selection of Stem Cells by Using Antibodies That Target Different CD34 Epitopes Yields Different Patterns of T-Cell Differentiation. <i>Stem Cells</i> , 2007, 25, 537-542.	3.2	8
94	Prophylaxis of <i>Pneumocystis carinii</i> pneumonia with atovaquone in children with leukemia. <i>Cancer</i> , 2007, 109, 1654-1658.	4.1	33
95	EBV lymphoproliferative disease of host origin after haploidentical stem cell transplantation. <i>Pediatric Blood and Cancer</i> , 2007, 49, 869-872.	1.5	7
96	Expanded Natural Killer Cells for Cellular Therapy of Acute Myeloid Leukemia.. <i>Blood</i> , 2007, 110, 2743-2743.	1.4	2
97	KIR-incompatible hematopoietic-cell transplantation for poor prognosis infant acute lymphoblastic leukemia. <i>Blood</i> , 2006, 107, 1238-1239.	1.4	21
98	Diagnostic Challenge in Recurrent Skin Rash After Autologous Bone Marrow Transplantation. <i>Journal of Pediatric Hematology/Oncology</i> , 2006, 28, 525-528.	0.6	5
99	Cidofovir for the Treatment of Adenoviral Infection in Pediatric Hematopoietic Stem Cell Transplant Patients. <i>Transplantation</i> , 2006, 81, 1398-1404.	1.0	198
100	Allogeneic graft-versus-hepatoblastoma effect. <i>Pediatric Blood and Cancer</i> , 2006, 46, 501-505.	1.5	20
101	Outcome of hematopoietic stem cell transplantation for pediatric patients with therapy-related acute myeloid leukemia or myelodysplastic syndrome. <i>Pediatric Blood and Cancer</i> , 2006, 47, 931-935.	1.5	51
102	Neuroendocrine Complications of Cancer Therapy. , 2005, , 51-80.		5
103	Human α T Cells From G-CSF-Mobilized Donors Retain Strong Tumoricidal Activity and Produce Immunomodulatory Cytokines After Clinical-Scale Isolation. <i>Journal of Immunotherapy</i> , 2005, 28, 73-78.	2.4	30
104	Prediction of T-cell reconstitution by assessment of T-cell receptor excision circle before allogeneic hematopoietic stem cell transplantation in pediatric patients. <i>Blood</i> , 2005, 105, 886-893.	1.4	73
105	Phenotype and function of human natural killer cells purified by using a clinical-scale immunomagnetic method. <i>Cancer Immunology, Immunotherapy</i> , 2005, 54, 389-394.	4.2	32
106	Comparison of Killer Ig-Like Receptor Genotyping and Phenotyping for Selection of Allogeneic Blood Stem Cell Donors. <i>Journal of Immunology</i> , 2005, 174, 6540-6545.	0.8	148
107	Combination Immunotherapy with Clinical-Scale Enriched Human α T cells, hu14.18 Antibody, and the Immunocytokine Fc-IL7 in Disseminated Neuroblastoma. <i>Clinical Cancer Research</i> , 2005, 11, 8486-8491.	7.0	47
108	Determinants of Antileukemia Effects of Allogeneic NK Cells. <i>Journal of Immunology</i> , 2004, 172, 644-650.	0.8	397

#	ARTICLE	IF	CITATIONS
109	Cyclooxygenase-2 Inhibition to Treat Radiation-Induced Brain Necrosis and Edema. <i>Journal of Pediatric Hematology/Oncology</i> , 2004, 26, 253-255.	0.6	19
110	Tâ€cell alloreactivity dominates natural killer cell alloreactivity in minimally Tâ€cellâ€depleted HLAâ€nonâ€identical paediatric bone marrow transplantation. <i>British Journal of Haematology</i> , 2003, 123, 323-326.	2.5	124
111	Extended Follow-up of Long-Term Survivors of Childhood Acute Lymphoblastic Leukemia. <i>New England Journal of Medicine</i> , 2003, 349, 640-649.	27.0	415
112	Possible Allogeneic Graft-Versus-Tumor Effect in Childhood Melanoma. <i>Journal of Pediatric Hematology/Oncology</i> , 2003, 25, 982-986.	0.6	13
113	Etiology and Outcome of Graft Failure in Pediatric Hematopoietic Stem Cell Transplant Recipients. <i>Journal of Pediatric Hematology/Oncology</i> , 2003, 25, 955-959.	0.6	32
114	Outcomes of Growth Hormone Replacement Therapy in Survivors of Childhood Acute Lymphoblastic Leukemia. <i>Journal of Clinical Oncology</i> , 2002, 20, 2959-2964.	1.6	90
115	Second malignancy after treatment of childhood non-Hodgkin lymphoma. <i>Cancer</i> , 2001, 92, 1959-1966.	4.1	59
116	Human CD34+ cell preparations contain over 100-fold greater NOD/SCID mouse engrafting capacity than do CD34â€ cell preparations. <i>Experimental Hematology</i> , 2001, 29, 910-921.	0.4	49
117	Late Effects of Treatment in Survivors of Childhood Acute Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2000, 18, 3273-3279.	1.6	213
118	Ex Vivo Culture of Cord Blood CD34+ Cells Expands Progenitor Cell Numbers, Preserves Engraftment Capacity in Nonobese Diabetic/Severe Combined Immunodeficient Mice, and Enhances Retroviral Transduction Efficiency. <i>Human Gene Therapy</i> , 1999, 10, 2927-2940.	2.7	38
119	Human Hematopoietic Stem/Progenitor Cells Generate CD5⁺ B Lymphoid Cells in NOD/SCID Mice. <i>Stem Cells</i> , 1999, 17, 242-252.	3.2	16
120	A human-murine chimera model for in utero human hematopoietic stem cell transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 1999, 5, 1-7.	2.0	20
121	Quantity and quality of engrafting cells in cord blood and autologous mobilized peripheral blood. <i>Biology of Blood and Marrow Transplantation</i> , 1999, 5, 69-76.	2.0	34
122	LONG-TERM COMPLETE REMISSION AND IMMUNE TOLERANCE AFTER INTENSIVE CHEMOTHERAPY FOR LYMPHOPROLIFERATIVE DISORDERS COMPLICATING LIVER TRANSPLANT1. <i>Transplantation</i> , 1999, 67, 1487-1489.	1.0	3
123	COMPARISONS OF ALLOREACTIVE POTENTIAL OF CLINICAL HEMATOPOIETIC GRAFTS1. <i>Transplantation</i> , 1999, 68, 628-635.	1.0	15
124	Hematopoietic stem cell and natural killer cell transplantation. , 0, , 527-548.		0